NCT04507217View on ClinicalTrials.gov

Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

November 15, 2022

Study Completion Date

January 30, 2023

Conditions
NSCLC Stage IVBrain MetastasesPD-1 Antibody
Interventions
DRUG

Tislelizumab, Carboplatin, Pemetrexed

"Tislelizumab: 200mg administered intravenously (IV) on Day 1 of each 21-day cycle~Carboplatin: AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles~Pemetrexed: 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle"

Trial Locations (2)

510060

Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou

Unknown

Guangxi Medical University Affiliated Tumor Hospital, Nanning

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC | Biotech Hunter | Biotech Hunter